EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Limitations of the NMN-BBB score in capturing therapeutic accessibility

Nathalie L Albert, Matthias Preusser

The Lancet Medical Imaging & Theranostics · 2026

DOI: 10.1016/j.lanmit.2026.100018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Lancet Medical Imaging & Theranostics, 2026. Verfasst von Nathalie L Albert und 1 weiteren Autor:innen. Die Arbeit nennt 2 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We have read with great interest the Correspondence by Ali Nabavizadeh and colleagues,1 in which the authors comment on our conceptual introduction of the Nuclear Medicine and Neuro-Oncology blood–brain barrier (NMN-BBB) score. In particular, we appreciate that they provide a summary of and elaborate on some of the considerations provided in the section Key recommendations for future research and in panel 2 of the Personal View.2 We agree that further studies are needed to determine whether the NMN-BBB score can predict drug penetration into glioblastoma tissue and whether such penetration results in sufficient antitumour activity.

Zitieren

APA

Albert, N. L., & Preusser, M. (2026). Limitations of the NMN-BBB score in capturing therapeutic accessibility. The Lancet Medical Imaging & Theranostics. https://doi.org/10.1016/j.lanmit.2026.100018

Vancouver

Albert NL, Preusser M. Limitations of the NMN-BBB score in capturing therapeutic accessibility. The Lancet Medical Imaging & Theranostics. 2026. doi:10.1016/j.lanmit.2026.100018

BibTeX
@article{Albert2026,
  author = {Albert, Nathalie L and Preusser, Matthias},
  title = {Limitations of the NMN-BBB score in capturing therapeutic accessibility},
  journal = {The Lancet Medical Imaging & Theranostics},
  year = {2026},
  doi = {10.1016/j.lanmit.2026.100018}
}
Kostenlos starten →